Search Results - Van Syoc, Merrie

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis

    Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis by Eichenfield, Lawrence F., Call, Robert S., Forsha, Douglass W., Fowler, Joseph, Hebert, Adelaide A., Spellman, Mary, Stein Gold, Linda F., Van Syoc, Merrie, Zane, Lee T., Tschen, Eduardo

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study

    Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study by Tom, Wynnis L., Van Syoc, Merrie, Chanda, Sanjay, Zane, Lee T.

    Published in Pediatric dermatology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study

    Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study by Zane, Lee T., Kircik, Leon, Call, Robert, Tschen, Eduardo, Draelos, Zoe Diana, Chanda, Sanjay, Van Syoc, Merrie, Hebert, Adelaide A.

    Published in Pediatric dermatology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Maximal use systemic exposure study evaluating AN2728, a novel boron-based small molecule, for the treatment of pediatric and adolescent subjects with mild-to-moderate atopic dermatitis (THER2P.959)

    Maximal use systemic exposure study evaluating AN2728, a novel boron-based small molecule, for the treatment of pediatric and adolescent subjects with mild-to-moderate atopic derma... by Kircik, Leon, Call, Robert, Tschen, Eduardo, Draelos, Zoe, Van Syoc, Merrie, Zane, Lee, Hebert, Adelaide

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Long-term Safety of Crisaborole, a Novel, Nonsteroidal, Topical, Anti-inflammatory, Phosphodiesterase 4 Inhibitor in Children and Adults with Mild to Moderate Atopic Dermatitis

    Long-term Safety of Crisaborole, a Novel, Nonsteroidal, Topical, Anti-inflammatory, Phosphodiesterase 4 Inhibitor in Children and Adults with Mild to Moderate Atopic Dermatitis by Eichenfield, Lawrence F., Call, Robert S., Forsha, Douglass W., Fowler, Joseph, Hebert, Adelaide A., Spellman, Mary, Stein Gold, Linda F., Van Syoc, Merrie, Zane, Lee T., FAAD, Tschen, Eduardo

    Published in Pediatrics (Evanston)
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Long-term safety of Crisaborole Topical Ointment, 2%, in children and adults with mild- to-moderate atopic dermatitis

    Long-term safety of Crisaborole Topical Ointment, 2%, in children and adults with mild- to-moderate atopic dermatitis by Zane, Lee Thomas, Eichenfield, Lawrence F., Call, Robert S., Forsha, Douglass W., Fowler, Joseph F., Hebert, Adelaide A., Spellman, Mary, Stein Gold, Linda F., Van Syoc, Merrie, Tschen, Eduardo H.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: